EyePoint Pharmaceuticals Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:$217.5M
Lead Investor(s):CR Group L.P.

Estimated Revenue & Financials

  • EyePoint Pharmaceuticals's estimated annual revenue is currently $3M per year.(?)
  • EyePoint Pharmaceuticals received $60.0M in venture funding in February 2019.
  • EyePoint Pharmaceuticals's estimated revenue per employee is $23,688
  • EyePoint Pharmaceuticals's total funding is $217.5M.

Employee Data

  • EyePoint Pharmaceuticals has 125 Employees.(?)
  • EyePoint Pharmaceuticals grew their employee count by -38% last year.
  • EyePoint Pharmaceuticals currently has 2 job openings.

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products. As a leading provider of miniaturized, sustained-release drug delivery products, we focus on improving the lives of patients with serious eye disorders in indications with high unmet medical need. With 3 FDA-approved sustained release treatments in ophthalmology we continue to push the evolution of our Durasert Technology platform to further enhance treatments for wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power